Stephens initiated coverage of Enovis with an Overweight rating and $72 price target. The orthopedic medical device company has a broad portfolio of joint replacement devices and implants as well as a full suite of prevention and recovery products, notes the analyst, who believes the company can continue to drive above market reconstruction growth as it continues to take share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ENOV:
- Enovis™ to Highlight Latest Technologies Across the Orthopedic Care Continuum at 2024 AAOS Annual Meeting
- Enovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
- Enovis to showcase Foot & Ankle Offerings at ACFAS meeting
- Enovis to Host Fourth Quarter and Full Year 2023 Conference Call on February 22nd
- Enovis introduces the DonJoy ROAM OA knee brace
